The DEA Just Admitted There Isn't Enough ADHD Medication. People in Recovery Have Been Paying for That.

If you have ADHD and you are in recovery, you probably know the routine by now: the pharmacist says they are out, you call four more pharmacies, one has the generic but not your dose, your prescriber has to write a new script because it is a controlled drug, and by day three without it your focus is gone and the old shortcuts start talking. On November 10, the Drug Enforcement Administration published an order that, read plainly, admits the shortage was real.

When the government rations a medication that keeps people stable, people in recovery are the ones who find out what replaces it.

The order in the Federal Register, signed by DEA Administrator Terrance Cole on November 4, raises the 2026 national production limits, called aggregate production quotas, for the main ADHD stimulants. The cap on d-amphetamine went from 26.45 million grams to about 37.1 million, roughly 40 percent more. Mixed d,l-amphetamine went up about 31 percent, and methylphenidate, the drug in Ritalin and Concerta, about 19 percent. The DEA said it checked the FDA shortage list and found manufacturers reporting domestic shortages of amphetamine mixed-salts tablets and methylphenidate tablets, and that the FDA expects U.S. medical need for these drugs to rise about 23 percent this year over last. It also raised the limit on hydromorphone, an opioid pain injection that has been short in hospitals.

Here is the gate before anyone celebrates. A quota is a ceiling, not a shipment. Manufacturers still have to source the raw ingredient, make the pills and move them through distribution, and that usually takes months. Insurers still require prior authorization, and every refill is still a new paper or electronic script.

Why this is a recovery story and not just a pharmacy story: untreated ADHD and addiction travel together, and stable treatment helps. A study of nearly 3 million people with ADHD in U.S. insurance records, published in the American Journal of Psychiatry and led by Patrick Quinn, found that men had 35% lower odds, and women 31% lower odds, of an emergency visit for a substance problem in months they were taking their medication compared with months they were not. That is an association within the same people over time, not a trial, but it is the kind of evidence that should make a shortage feel like a public health problem. A gap in medication is not just a bad week at work. For some people, it is the opening an old habit was waiting for.

For prescribers and case managers, the move this week: for any patient in recovery on a stimulant, ask whether they have missed doses in the last three months because of pharmacy stock, and if so, write down which pharmacy reliably fills it and whether a different formulation is available. Flag those patients as high risk for a return to use during gaps. More on stimulants and policy here.

If you are the one calling pharmacies, call before you run out, not after, and tell your prescriber the shortage is happening to you. Your medication is not a luxury, and you are not being difficult for needing it.